Investigational drug · Phase 2
spartalizumab
Also called: PDR001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
310
Any phase or sponsor naming "spartalizumab"
First trial start
2023
Feb 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "spartalizumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
Approved drugs for the same conditions: Myelodysplastic syndromes · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "spartalizumab" as an intervention, largest first.
- PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal CarcinomaPivotal-lookingNot yet recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT06900218 · 664 participants (planned) · Start May 1, 2025 · Primary completion May 1, 2030
Drug: Sintilimab; Capecitabine · For: Nasopharyngeal Carcinoma (NPC)
Sites: Guangzhou, China
- An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have SpreadPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02658890 · 627 participants · Start Apr 14, 2016 · Primary completion Oct 26, 2021
Drug: BMS-986205; Nivolumab and 1 more · For: Advanced Cancer; Melanoma; Non-Small Cell Lung Cancer
Sites: Tucson, Arizona; La Jolla, California; Tampa, Florida · 47 sites in all
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06475300 · 570 participants (planned) · Start Jun 25, 2024 · Primary completion Jun 2027
Drug: BL-B01D1; PD-1 Monoclonal Antibody and 1 more · For: Non-small Cell Lung Cancer; Nasopharyngeal Carcinoma; Solid Tumor
Sites: Guangzhou, China
- A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced MelanomaPivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT02967692 · 568 participants · Start Feb 17, 2017 · Primary completion Aug 11, 2020
Drug: Spartalizumab; Dabrafenib and 1 more · For: Melanoma
Sites: Encinitas, California; Orange, California; San Francisco, California · 179 sites in all
- Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal CarcinomaPivotal-lookingRecruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT05342792 · 556 participants (planned) · Start Apr 17, 2022 · Primary completion Jun 2027
Drug: PD-1 antibody; Capecitabine · For: Nasopharyngeal Carcinoma
Sites: Guangzhou, China
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialPivotal-lookingRecruiting
City of Hope Medical CenterAcademic, hospital or other
NCT07288034 · 535 participants (planned) · Start May 1, 2026 · Primary completion Oct 8, 2028
Drug: Adagrasib; Anti-PD-L1 Monoclonal Antibody and 5 more · For: Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8
Sites: Goodyear, Arizona; Corona, California; Duarte, California · 13 sites in all
- A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic CancerPivotal-lookingCompleted
Pancreatic Cancer Action NetworkAcademic, hospital or other
NCT04229004 · 502 participants · Start Jan 31, 2020 · Primary completion Feb 5, 2025
Drug: Gemcitabine combined with nab-paclitaxel; Dose -mFOLFIRINOX and 3 more · For: Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 25 sites in all
- Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerActive, not recruiting
Agenus Inc.Industry
NCT03860272 · 499 participants · Start Mar 20, 2019 · Primary completion Jan 13, 2025
Drug: Botensilimab; Balstilimab · For: Advanced Cancer; Angiosarcoma; Colorectal Cancer Without Liver Metastases and 5 more
Sites: Scottsdale, Arizona; Duarte, California; Los Angeles, California · 18 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT02460224 · 490 participants · Start Jun 17, 2015 · Primary completion Dec 31, 2020
Drug: LAG525; PDR001 · For: Advanced Solid Tumors
Sites: New York, New York; Durham, North Carolina; Houston, Texas · 24 sites in all
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07729956 · 436 participants (planned) · Start Sep 2, 2026 · Primary completion Dec 2029
Drug: BL-B01D1; PD-1 monoclonal antibody and 1 more · For: Triple-Negative Breast Cancer (TNBC)
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Phase II, Open-Label, Randomized Study.
Pelletier M, Yang J, Joshi M, et al. · Clin Cancer Res 2026
- COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.
Ribas A, Robert C, Schadendorf D, et al. · J Clin Oncol 2026
- Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma.
Garralda E, Schöffski P, Oberoi A, et al. · Eur J Cancer 2026
- Efficacy and Safety of Canakinumab Compared With Standard Therapy for the Treatment of Non-Small Cell Lung Cancer (NSCLC): A Systematic Review.
Izadpanah K, Rezaei M, Nejadghaderi SA, et al. · Cancer Rep (Hoboken) 2026
- Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 study.
Dos Santos M, Lequesne J, Piessen G, et al. · Eur J Cancer 2026
- Global safety profile of PD-1/PD-L1 inhibitors in hepatic autoimmune disorders: A global disproportionality analysis.
Oh J, Kong J, Hwang J, et al. · Medicine (Baltimore) 2025
Also in development for Myelodysplastic Syndromes
- AND017Phase 36 trials
Kind Pharmaceuticals LLC · Anemia Due to Chronic Kidney Disease, β -Thalassemia, Cancer-Related Anemia
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- BL-M11D1Phase 32 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Acute Myeloid Leukemia, Myelodysplastic Syndromes
- RoxadustatFG-4592, ASP1517Phase 32 trials
Astellas · Chronic Kidney Disease, Renal Anemia, Myelodysplastic Syndromes
- ASTX030cedazuridine + azacitidinePhase 31 trial
Taiho Oncology, Inc. · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm
- RimiducidAP1903Phase 23 trials
Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child
- bexmarilimabFP-1305Phase 22 trials
Faron Pharmaceuticals Ltd · Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- DISC-0974Phase 22 trials
Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.